June 24, 2017 9:39 PM ET

Healthcare Equipment and Supplies

Company Overview of Rna Diagnostics Inc.

Company Overview

Rna Diagnostics Inc. develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company has clinical trials and collaborations in progress at multiple clinical research centers in Canada, Germany, Italy, Japan, Sweden, the United Kingdom, and the United States. Rna Diagnostics Inc. was founded in 2010 and is based in Toronto, Canada with a RNA diagnostics’ laboratory in Sudbury, Canada.

MaRS Centre

Heritage Building

101 College Street

Suite HL20-4

Toronto, ON M5G 1L7


Founded in 2010

Key Executives for Rna Diagnostics Inc.

Chief Executive Officer and President
Age: 47
Chief Financial Officer and Director
Chief Innovation Officer and Director
Principal Scientist
Executive Vice President of Corporate Development and Director
Compensation as of Fiscal Year 2016.

Rna Diagnostics Inc. Key Developments

Rna Diagnostics Inc. Announces Launch of BREVITY

Rna Diagnostics Inc. has announced the launch of BREVITY (Breast Cancer Response EValuation for Individualized TherapY), a clinical trial to validate the RNA Disruption Assay (RDA) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will include 500+ patients with invasive breast cancer, scheduled to receive neoadjuvant chemotherapy, in 40 centers across North America and Europe. The objectives and design of BREVITY reflect feedback received from Key Opinion Leaders in breast cancer research from centers in Europe, Canada and the US. Accrual of patients will begin in the second half of 2017. BREVITY will include patients with all subtypes of invasive breast cancer (stage II and stage III), scheduled to receive standard of care neoadjuvant chemotherapy and targeted drugs. Phase I (Training Phase) of BREVITY will include an analysis of 113 patients for final determination of response zone cutoffs. Phase II (Validation Phase) will include 347 fully evaluable patients. The primary endpoint of BREVITY is the ability of RDA to predict, at 14-21 days after initiation of chemotherapy, the absence or presence of a pathologic Complete Response (pCR) at surgery. Patient accrual, as well as the primary endpoint of the trial, is expected to be achieved in 2019. In a recent study, a high RDA score also proved useful in predicting long-term disease-free survival after neoadjuvant chemotherapy in breast cancer patients. Survival data will also be collected in the BREVITY trial.

Rna Diagnostics Inc. Presents at Redefining Early Stage Investments (RESI) Conference, Sep-13-2016

Rna Diagnostics Inc. Presents at Redefining Early Stage Investments (RESI) Conference, Sep-13-2016 . Venue: The Westin Copley Place, 10 Huntington Ave, Boston, MA 02116, United States.

Similar Private Companies By Industry

Company Name Region
A.R. Medicom, Inc. Americas
ABK Biomedical Inc. Americas
Adaptaide Inc. Americas
Adjuvant Therapeutics Inc. Americas
Advanced Bioelectric Corp. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Rna Diagnostics Inc., please visit www.rnadiagnostics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.